| Date | Title | Description | |
|---|---|---|---|
| 12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 04 Oct 2022 | On business and financial situation | The Company informs that it has signed a joint venture agreement with Càrniques Ceirà and Grupo Costa to construct a plant for the production of compounds of high technological value. | Download |
| 03 Oct 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2022 | Download |
| 29 Jul 2022 | Other relevant información | On 26 July 2022 the public deed relating to the Company’s share capital decrease was registered with the Commercial Registry of Madrid. | Download |
| 27 Jul 2022 | On business and financial situation | The Company releases the press release related to the first half 2022 financial results | Download |
| 27 Jul 2022 | On business and financial situation | The Company releases the first half 2022 financial results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
| 03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
| 07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |